Placing in-vitro heteroresistance in the context of clinical results.

Bassetti, Matteo; Echols, Roger; Koren, Andrew; Karas, Andreas; Longshaw, Chris; Yamano, Yoshinori; Den Nagata, Tsutae

Bassetti, Matteo; Echols, Roger; Koren, Andrew; Karas, Andreas; Longshaw, Chris; Yamano, Yoshinori; Den Nagata, Tsutae.

Afiliação

Bassetti M; Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, Genoa and Hospital Policlinico San Martino IRCCS, Genoa, Italy.
Echols R; Infectious Disease Drug Development Consulting, Easton, CT, USA.
Koren A; Shionogi, Florham Park, NJ, USA.
Karas A; Shionogi Europe, London WC2B 6UF, UK.
Longshaw C; Shionogi Europe, London WC2B 6UF, UK. Electronic address: christopher.longshaw@shionogi.eu.
Yamano Y; Shionogi, Osaka, Japan.
Den Nagata T; Shionogi, Osaka, Japan.

Lancet Infect Dis ; 21(7): 908-909, 2021 07.

Article em En | MEDLINE | ID: mdl-34174228

Assuntos

Antibacterianos; Antibacterianos/uso terapêutico; Humanos; Testes de Sensibilidade Microbiana

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antibacterianos Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google